ApiFix Ltd., a Misgav, Israel- and Boston, MA-based medical device company, completed its undisclosed Series B equity financing.
A new US-based investor led the round with participation from existing shareholders.
The company us preparing for US commercial launch of its MID-C System for young scoliosis patients.
Founded in 2011 and led Paul Mraz, CEO, and Yizhar Floman MD, Chief Medical Officer, ApiFix is a motion-preservation scoliosis correction company developing Minimally Invasive Deformity Correction (MID-C) system, a posterior dynamic deformity correction system that enables surgeons to perform a unique treatment providing permanent curve correction while retaining spine flexibility, all via a minimally invasive surgical approach.
The MID-C system acts as an “internal brace” with a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time and is removable.
It has CE Mark approval and is available in Europe, Israel, Singapore and Canada.
ApiFix is a portfolio company of The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY).